Jessica Hochberg

Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice

Yaya Chu, Jessica Hochberg, Ashlin Yahr et al. · Cancer Immunology Research · 2014 · 168 citations · Full text

Life Sciences, Immunology, Oncology +16

Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature <scp>B</scp>‐<scp>NHL</scp>: a <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup <scp>R</scp>eport

Paul J. Galardy, Jessica Hochberg, Sherrie L. Perkins et al. · British Journal of Haematology · 2013 · 60 citations · Full text

Medicine, Hematology, Pediatrics +13

Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial

Sarah H. O’Brien, Vilmarie Rodriguez, Glen Lew et al. · The Lancet Haematology · 2023 · 48 citations

Medicine, Hematology, Pediatrics +17

Characterization of natural killer and natural killer–like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: Implications for adoptive cellular immunotherapy

Janet Ayello, Carmella van de Ven, Evan Cairo et al. · Experimental Hematology · 2009 · 35 citations

Life Sciences, Cell Biology, Immunology +17

Rasburicase: future directions in tumor lysis management

Jessica Hochberg, Mitchell S. Cairo · Expert Opinion on Biological Therapy · 2008 · 24 citations

Pharmacy, Oncology, Pharmacotherapy +10